Why the study?
Survivors of childhood acute lymphoblastic leukemia may experience endocrine dysfunction affecting growth and puberty, which requires evaluation.
Does prophylactic cranial radiation compared to chemotherapy alone affect growth and pubertal patterns in young survivors of childhood acute lymphoblastic leukemia?
Cohort (n=183)
Does prophylactic cranial radiation compared to chemotherapy alone affect growth and pubertal patterns in young survivors of childhood acute lymphoblastic leukemia?
Childhood ALL survivors treated with prophylactic cranial radiation have a higher risk of short stature and precocious puberty compared to those receiving chemotherapy alone, while both groups face increased risks of overweight and obesity.
Answers are grounded in this paper and cite their sources.
May warrant closer endocrine surveillance in ALL survivors; leaves open need for prospective validation of treatment-specific effects.
BACKGROUND: Survivors of acute lymphoblastic leukemia (ALL) may experience endocrine dysfunction. This study evaluated growth and pubertal patterns in survivors of childhood ALL. METHODS: Longitudinal assessment of anthropometric measurements and pubertal status was performed in a retrospective cohort of survivors (n=183). Median age at last endocrine visit was 16.1 years (range 8.2-27.6); median follow-up time was 8.7 years (range 3-21.4). RESULTS: Treatment with chemotherapy+prophylactic cranial radiation (pCRT, n=29) was associated with lower mean height standard deviation score (SDS) than chemotherapy alone (n=154) (p=0.001) and higher prevalence of adult short stature (13% vs. 2.2%). Mean age at pubertal onset was normal (girls: 10.3±1.3 years; boys: 12.0±1.3 years). Precocious puberty, diagnosed in 8.7% of patients, was more prevalent in pCRT-treated girls. Rates of overweight and obesity were 22.9% and 9.3%, respectively. Predictors of endocrine disorders were pCRT (p=0.031) and female gender (p=0.041); of obesity, higher body mass index (BMI)-SDS at diagnosis (p=0.001); and of short stature, lower height-SDS at diagnosis (p=0.038). CONCLUSIONS: Most childhood ALL survivors given chemotherapy alone attain normal adult height and puberty. Childhood ALL survivors are at increased risk of overweight, especially those with increased BMI at diagnosis. Clinicians should screen for overweight early in survivorship and introduce early interventions.
No takes yet. Share an insight, caveat, or question.
Elitzur et al. (2017) conducted a cohort in childhood acute lymphoblastic leukemia (ALL) (n=183). Chemotherapy + prophylactic cranial radiation (pCRT) vs. Chemotherapy alone was evaluated on adult short stature.
Synapse has enriched 10 related papers. Consider them for comparative context: